ECQ0 Stock Overview
A clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Neurizon Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.11 |
| 52 Week High | AU$0.25 |
| 52 Week Low | AU$0.041 |
| Beta | 1.6 |
| 11 Month Change | -12.22% |
| 3 Month Change | 48.69% |
| 1 Year Change | 159.76% |
| 33 Year Change | 96.00% |
| 5 Year Change | 97.80% |
| Change since IPO | -88.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| ECQ0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -4.3% | -1.2% | -0.02% |
| 1Y | 159.8% | -20.1% | 8.2% |
Return vs Industry: ECQ0 exceeded the German Pharmaceuticals industry which returned -22% over the past year.
Return vs Market: ECQ0 exceeded the German Market which returned 7.4% over the past year.
Price Volatility
| ECQ0 volatility | |
|---|---|
| ECQ0 Average Weekly Movement | 23.8% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ECQ0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: ECQ0's weekly volatility has decreased from 30% to 24% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Michael Thurn | www.neurizon.com |
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease.
Neurizon Therapeutics Limited Fundamentals Summary
| ECQ0 fundamental statistics | |
|---|---|
| Market cap | €57.70m |
| Earnings (TTM) | -€5.55m |
| Revenue (TTM) | €525.28k |
109.8x
P/S Ratio-10.4x
P/E RatioIs ECQ0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ECQ0 income statement (TTM) | |
|---|---|
| Revenue | AU$841.71k |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$841.71k |
| Other Expenses | AU$9.74m |
| Earnings | -AU$8.90m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.018 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,057.36% |
| Debt/Equity Ratio | 0% |
How did ECQ0 perform over the long term?
See historical performance and comparison